We find that the “contemporary” assay and its result may have affected clinical decision with a significant trend toward earlier immunosuppression in the Ab-positive as well as the high Ab-titer groups.
← all excerpts
PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy.
1
—
—